<DOC>
	<DOCNO>NCT00388063</DOCNO>
	<brief_summary>This study evaluate safety efficacy atiprimod treatment patient low intermediate grade neuroendocrine carcinoma metastatic unresectable local-regional cancer either symptom ( diarrhea , flush and/or wheeze ) despite standard therapy ( octreotide ) progression neuroendocrine tumor ( ) .</brief_summary>
	<brief_title>Safety Efficacy Atiprimod Treatment Patients With Low Intermediate Grade Neuroendocrine Carcinoma</brief_title>
	<detailed_description>For carcinoid , despite many cytotoxic chemotherapy trial conduct , regimen demonstrate response rate 20 % use criterion 50 % reduction bidimensionally measurable disease . In recently report ECOG phase III study chemotherapy carcinoid tumor ( E1281 ) , patient randomly assign treatment 5-fluorouracil ( 5FU ) plus doxorubicin 5FU plus streptozocin . The median progression free survival duration disappoint . They 4.5 month 5FU plus doxorubicin arm 5.3 month 5FU plus streptozocin arm . Overall survival duration record trial also suboptimal 15 24 month respectively . There clear survival benefit cytotoxic chemotherapy . This phase II , multi-center , open-label study safety efficacy atiprimod treatment patient low intermediate grade neuroendocrine carcinoma metastatic unresectable local-regional cancer either symptom ( diarrhea , flush and/or wheeze ) despite standard therapy ( octreotide ) progression neuroendocrine tumor ( ) ( define appearance one new lesion 20 % increase sum long diameter target lesion 6 month prior enrollment ) . A maximum 40 evaluable patient enrol study . Atiprimod administer orally single daily dose 120 mg/day 14 day , follow 14-day treatment-free period ( i.e. , 1 treatment cycle = 28 day ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>Patient must document histologic proof low intermediate grade neuroendocrine carcinoma . Both carcinoid ( site ; atypical/intermediate grade carcinoid allow ) islet cell ( pancreatic endocrine tumor ) eligible . Patient neuroendocrine tumor associate MEN1 syndrome eligible . Patients must either metastatic unresectable localregional cancer . Patients brain metastasis allow study , must evaluable target lesion elsewhere . Patients must measurable disease , define RECIST . Patients must either symptoms ( diarrhea , flush and/or wheeze ) despite standard therapy ( octreotide ) progression neuroendocrine tumor ( ) ( define appearance one new lesion 20 % increase sum long diameter target lesion 6 month prior enrollment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Neuroendocrine</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Atiprimod</keyword>
	<keyword>Carcinoid</keyword>
</DOC>